Investor Webinar
TheraCryf plc will host an investor webinar on April 24, 2026, at 10:00 am BST, featuring the CEO and COO to discuss progress in their lead orexin-1 receptor antagonist program for addiction, which is moving towards clinical readiness and first-in-human studies. The company is also advancing its dopamine transporter modulator program for fatigue and has a legacy oncology program. Investors can submit questions in advance via the Investor Meet Company platform.
Select text to share a quote on X · sign in to keep highlights & notes in your TCF notes
TheraCryf plc (AIM: TCF), the biotech company developing new medicines for addiction and other neuropsychiatric disorders, today announces that Dr Huw Jones, Chief Executive Officer and Dr Helen Kuhlman, Chief Operating Officer, will host an investor webinar on Friday, 24 April 2026 at 10.00 am (BST).
The webinar will focus on the Company's recent announcements, including progress in its lead orexin-1 (Ox-1) receptor antagonist programme for addiction as it moves towards clinical readiness, alongside broader strategic developments as TheraCryf advances Ox-1 towards first-in-human studies.
The presentation is open to all existing and potential shareholders. Questions can be submitted pre-event via your Investor Meet Company dashboard up until Thursday, 23 April 2026, 9.00 am (BST), or at any time during the live presentation. Investors can sign up to Investor Meet Company for free and add to meet TheraCryf via: https://www.investormeetcompany.com/theracryf-plc/register-investor
Investors who already follow TheraCryf on the Investor Meet Company platform will automatically be invited.
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.